These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18356688)

  • 1. Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesicle-based drug delivery formulation of pravastatin.
    Broz P; Ben-Haim N; Grzelakowski M; Marsch S; Meier W; Hunziker P
    J Cardiovasc Pharmacol; 2008 Mar; 51(3):246-52. PubMed ID: 18356688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation.
    Coimbra M; Banciu M; Fens MH; de Smet L; Cabaj M; Metselaar JM; Storm G; Schiffelers RM
    J Control Release; 2010 Dec; 148(3):303-10. PubMed ID: 20869410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of vulnerable plaque macrophages with polymer-based nanostructures.
    Broz P; Marsch S; Hunziker P
    Trends Cardiovasc Med; 2007 Aug; 17(6):190-6. PubMed ID: 17662913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin.
    Schindler C; Thorns M; Matschke K; Tugtekin SM; Kirch W
    Clin Ther; 2007 Jan; 29(1):172-6. PubMed ID: 17379057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event.
    Brudi P; Reckless JP; Henry DP; Pomykaj T; Lim ST; Massaad R; Vandormael K; Johnson-Levonas AO
    Cardiology; 2009; 113(2):89-97. PubMed ID: 19018143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro.
    Skottheim IB; Gedde-Dahl A; Hejazifar S; Hoel K; Asberg A
    Eur J Pharm Sci; 2008 Apr; 33(4-5):317-25. PubMed ID: 18294823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recurrent acute pancreatitis during pravastatin-therapy].
    Becker C; Hvalic C; Delmore G; Krähenbühl S; Schlienger R
    Praxis (Bern 1994); 2006 Jan; 95(4):111-6. PubMed ID: 16485606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite.
    Gustavson LE; Schweitzer SM; Koehne-Voss S; Achari R; Chira TO; Esslinger HU; Yannicelli HD
    J Clin Pharmacol; 2005 Aug; 45(8):947-53. PubMed ID: 16027406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of pravastatin on the function of dendritic cells in patients with coronary heart disease.
    Li X; Liu C; Cui J; Dong M; Peng CH; Li QS; Cheng JL; Jiang SL; Tian Y
    Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):101-6. PubMed ID: 19143751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrophobic statins induce autophagy in cultured human rhabdomyosarcoma cells.
    Araki M; Motojima K
    Biochem Biophys Res Commun; 2008 Mar; 367(2):462-7. PubMed ID: 18178158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1.
    Wali VB; Bachawal SV; Sylvester PW
    Exp Biol Med (Maywood); 2009 Jun; 234(6):639-50. PubMed ID: 19359655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired ichthyosis with pravastatin.
    Sparsa A; Boulinguez S; Le Brun V; Roux C; Bonnetblanc JM; Bedane C
    J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):549-50. PubMed ID: 17373993
    [No Abstract]   [Full Text] [Related]  

  • 13. Statin-associated adverse cognitive effects: survey results from 171 patients.
    Evans MA; Golomb BA
    Pharmacotherapy; 2009 Jul; 29(7):800-11. PubMed ID: 19558254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins and renal function. Is the compound and dose making a difference?
    Athyros VG; Karagiannis A; Kakafika A; Elisaf M; Mikhailidis DP
    Nephrol Dial Transplant; 2007 Mar; 22(3):963-4; author reply 964. PubMed ID: 17255130
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of statin therapy in patients with preexisting liver disease.
    Onofrei MD; Butler KL; Fuke DC; Miller HB
    Pharmacotherapy; 2008 Apr; 28(4):522-9. PubMed ID: 18363535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of hepatotropic targeting properties of allogenic and xenogenic erythrocyte ghosts in normal and liver-injured rats.
    Gressner OA; Lahme B; Koch M; Gressner AM
    Liver Int; 2008 Feb; 28(2):220-32. PubMed ID: 18069973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of glucose intolerance by combination of pravastatin and olmesartan in type II diabetic KK-A(y) mice.
    Kanno H; Iwai M; Inaba S; Senba I; Nakaoka H; Sone H; Mogi M; Horiuchi M
    Hypertens Res; 2009 Aug; 32(8):706-11. PubMed ID: 19478815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin.
    David S; Kümpers P; Lukasz A; Kielstein JT; Haller H; Fliser D
    J Hypertens; 2009 Aug; 27(8):1641-7. PubMed ID: 19390459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence reflectance imaging of macrophage-rich atherosclerotic plaques using an alphavbeta3 integrin-targeted fluorochrome.
    Waldeck J; Häger F; Höltke C; Lanckohr C; von Wallbrunn A; Torsello G; Heindel W; Theilmeier G; Schäfers M; Bremer C
    J Nucl Med; 2008 Nov; 49(11):1845-51. PubMed ID: 18927332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.